Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $89.7 million.

  • Heron Therapeutics' Total Current Liabilities rose 4.87% to $89.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.7 million, marking a year-over-year increase of 4.87%. This contributed to the annual value of $91.5 million for FY2024, which is 14.77% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Total Current Liabilities is $89.7 million, which was down 65.31% from $258.6 million recorded in Q2 2025.
  • Heron Therapeutics' Total Current Liabilities' 5-year high stood at $258.6 million during Q2 2025, with a 5-year trough of $71.1 million in Q4 2021.
  • In the last 3 years, Heron Therapeutics' Total Current Liabilities had a median value of $85.5 million in 2024 and averaged $99.4 million.
  • Per our database at Business Quant, Heron Therapeutics' Total Current Liabilities slumped by 30.68% in 2021 and then spiked by 221.98% in 2025.
  • Heron Therapeutics' Total Current Liabilities (Quarterly) stood at $71.1 million in 2021, then rose by 15.90% to $82.4 million in 2022, then declined by 3.24% to $79.7 million in 2023, then climbed by 14.77% to $91.5 million in 2024, then rose by 4.87% to $89.7 million in 2025.
  • Its Total Current Liabilities stands at $89.7 million for Q3 2025, versus $258.6 million for Q2 2025 and $88.6 million for Q1 2025.